HAPLN1 Human

HAPLN1 is a hyaluronan-binding protein, also referred to as a hyaladherin. It was initially characterized in cartilage proteoglycan preparations and is known to stabilize the interaction of aggrecan and hyaluronan in large multi-molecular aggregates that form the chondrocyte pericellular matrix . Additionally, HAPLN1 stabilizes the interaction of other aggregating chondroitin sulfate proteoglycans, such as versican and neurocan, with hyaluronan .

HAPLN1 is predicted to enable hyaluronic acid binding activity and is an extracellular matrix structural constituent conferring compression resistance . It is involved in central nervous system development and skeletal system development . The protein colocalizes with collagen-containing extracellular matrix, highlighting its role in maintaining the structural integrity of tissues .

HAPLN1 has been associated with various diseases, including Cerebral Creatine Deficiency Syndrome 1 and Cerebral Creatine Deficiency Syndrome . Its role in the tumor environment, particularly in colorectal cancer, has been studied extensively. Loss of HAPLN1 induces tumorigenesis in colorectal cancer by regulating the transforming growth factor (TGF)-β signaling pathway, which controls collagen deposition and mediates E-adhesion to control tumor growth .

Research has shown that HAPLN1 is crucial for the formation of a hyaluronan-rich matrix surrounding the cumulus cells, which is essential for ovulation and fertilization . The recombinant form of HAPLN1 is used in various research applications to study its role in ECM stabilization and its potential therapeutic applications in diseases related to ECM dysfunction.